Savara Inc (SVRA) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Savara Inc stock $3.08, price $4.47, that is 31.0% below the price, quality 28 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Savara Inc
SVRA · USExpensive (fair value 31% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.
How to read this chart
60‑month range $1.04 – $6.94 · fair‑value band $2.31 – $3.85 · the $4.47 price screens above the $3.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.
Every Wednesday you see whether Savara is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
Show moreShow less
The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Stock analysis
Savara Inc (SVRA) currently trades at $4.47, while our estimate is $3.08, 31% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $2.31 (bear) to $3.85 (bull), the price of $4.47 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Savara Inc reported revenue of $0 in FY2025 versus $1.0K in FY2021. Reported net income was −$119M in FY2025.
Key figures
Market cap $1.1B Small · EPS (TTM) $−0.6000 · Return on equity −151% · Return on assets (EBIT) −36.5% (5-year average) · Revenue (TTM) $1.0K · Free cash flow −$101M · Net cash $3.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −31%, SVRA screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director sold shares worth $2.2M and none bought.
- SaleDavid L LowranceChief Financial Officer394,528 shares at $5.68$2.2MJun 22, 2026
- SaleDavid A RamsayDirector20,000 shares at $6.06$121,200Dec 19, 2025
Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Savara Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs SVRA |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs SVRA |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs SVRA |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs SVRA |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs SVRA |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs SVRA |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs SVRA |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs SVRA |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs SVRA |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs SVRA |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Savara Inc (SVRA) overvalued or undervalued?
What is the fair value of SVRA?
What is the quality score of SVRA?
What is the price target for Savara Inc (SVRA)?
What is the Savara Inc stock forecast for 2026?
What is the revenue of Savara Inc (SVRA)?
What is the intrinsic value of Savara Inc (SVRA)?
Is Savara Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SVRA?
How much is Savara Inc worth?
What do the bullish and bearish scenarios say about SVRA?
How solid is the balance sheet of Savara Inc (SVRA)?
How far is SVRA from its 52-week high?
Which stocks are comparable to Savara Inc?
Is Savara Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Savara Inc (SVRA)?
What should I pay attention to with Savara Inc right now?
Key figures of Savara Inc
How large is the market capitalisation of Savara Inc (SVRA)?
What are the earnings per share of Savara Inc (SVRA)?
What is the return on equity of Savara Inc (SVRA)?
What is the EBIT return on assets of Savara Inc (SVRA)?
How much free cash flow does Savara Inc (SVRA) generate?
How much net cash does Savara Inc (SVRA) hold?
Watch Savara Inc in the live analysis
One click puts Savara Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.